Establishment Labs Holdings
Establishment Labs Holdings' revenue rose 27.1% to $211 million in fiscal 2025. Its operating margin was −18.5%, up from −30.1% a year earlier. Free cash flow was −$57 million. The diluted share count rose 5.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Establishment Labs Holdings does
Establishment Labs is a medical technology company that makes breast implants and related products for cosmetic and reconstructive surgery. It was incorporated in Costa Rica in 2004. Its main product line is Motiva Implants, silicone gel-filled breast implants, which it launched in October 2010 and which have produced most of its revenue.
Motiva Implants are registered for sale in over 100 countries, and its SmoothSilk round implants were approved in the United States. It sells through exclusive distributors and its own direct sales force. Its product families include round, oval and anatomical implants and a tissue expander. It says its implants carry safety features such as a smooth surface designed to reduce a hardening scar tissue problem and an electronically readable serial number.
The company also develops Mia Femtech, another product it has studied in clinical research, and it says it competes with companies that have more resources than it does.
Its biggest risks, as it describes them
- It has a short history in the United States and has lost money to date.
- Its results depend on the commercial success of Motiva Implants.
- FDA and other agency disruptions could slow approvals.
- Competitors with more resources, and pricing pressure, could cut its sales.
- Product liability claims could lead to big costs.
Income statement
Establishment Labs Holdings lost money in fiscal 2025: a net loss of $51 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 53 | 66 | 40 | 90 | 76 |
| Debt incl. finance leases | — | 176 | 189 | 0 | 248 |
| Net debt (negative means net cash) | — | 109 | 149 | −90 | 172 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 10.3x | 0.0x | 10.5x |
| Interest coverage | −2.8x | −3.4x | −4.2x | −2.4x | −1.5x |
| Current ratio | 3.5x | 3.9x | 3.1x | 3.6x | 3.0x |
| Quick ratio | 2.7x | 2.9x | 1.7x | 2.4x | 2.0x |
Cash flow
Projections
Project Establishment Labs Holdings' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Establishment Labs Holdings says to expect
- Full year 2026: revenue
Increasing revenue to more than $274 million, compared to the previous guidance of $269 million to $271 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Establishment Labs Holdings shares on the open market, and 4 insiders sold $35.5 million, $22.9 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 28, 2026 | JW Partners LPSee footnote 3 | Sold | 65,100 | $72.89 | $4.7 million | Form 4 |
| May 27, 2026 | JW Partners LPSee footnote 3 | Sold | 113 | $72.50 | $8,192 | Form 4 |
| May 26, 2026 | JW Partners LPSee footnote 3 | Sold | 25,320 | $74.39 | $1.9 million | Form 4 |
| May 21, 2026 | Jw Gp Llc10% owner | Sold | 16,999 | $71.40 | $1.2 million | Form 4 |
| May 20, 2026 | Jw Gp Llc10% owner | Sold | 3,580 | $70.56 | $252,605 | Form 4 |
| May 6, 2026 | Quiros Juan Jose ChaconDirector | Sold plan | 105,000 | $75.42 | $7.9 million | Form 4 |
| May 6, 2026 | JW Asset Management LLC10% owner | Sold | 60,000 | $75.63 | $4.5 million | Form 4 |
| May 4, 2026 | Quiros Juan Jose ChaconDirector | Sold plan | 7,751 | $70.48 | $546,300 | Form 4 |
| May 1, 2026 | Quiros Juan Jose ChaconDirector | Sold plan | 67,249 | $70.78 | $4.8 million | Form 4 |
| Apr 27, 2026 | Quiros Juan Jose ChaconDirector | Sold plan | 2,180 | $66.26 | $144,441 | Form 4 |
| Apr 24, 2026 | Quiros Juan Jose ChaconDirector | Sold plan | 30,178 | $65.78 | $2.0 million | Form 4 |
| Apr 23, 2026 | Quiros Juan Jose ChaconDirector | Sold plan | 42,642 | $65.43 | $2.8 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 5 of 9 | 3 of 9 |
| Rule of 40 | −56.2% | −38.4% | 0.2% |
| Altman Z'' | −3.04 | −1.65 | −2.10 |
| Accruals ratio | 4.2% | −8.5% | −0.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 2 of 9 | 5 of 9 | 3 of 9 |
Compare
Put Establishment Labs Holdings side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Establishment Labs Holdings | FY25 | 27.1% | −18.5% | −27.0% | −39.0% | — | 3 | |
| SI-BONE | FY25 | 20.2% | −11.1% | −4.5% | −26.3% | — | 6 | Compare |
| Axogen | FY25 | 20.2% | −3.5% | −1.3% | −4.9% | — | 5 | Compare |
| Cerus | FY25 | 16.1% | −3.7% | 0.5% | — | — | — | Compare |
| Orthopediatrics | FY25 | 15.4% | −16.6% | −6.8% | −8.2% | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 35 | 61 | 90 | 85 | 127 | 162 | 165 | 166 | 211 |
| Revenue growth | — | 76.5% | 46.3% | −5.5% | 49.6% | 27.6% | 2.1% | 0.5% | 27.1% |
| Gross profit | 18 | 36 | 55 | 52 | 85 | 107 | 107 | 110 | 146 |
| Research and development | 7 | 13 | 15 | 14 | 18 | 20 | 26 | 20 | 20 |
| Operating income | −20 | −24 | −31 | −28 | −25 | −40 | −65 | −50 | −39 |
| Net income | −35 | −21 | −38 | −38 | −41 | −75 | −78 | −85 | −51 |
| Diluted EPS (US$) | −3.41 | −1.22 | −1.86 | −1.63 | −1.72 | −3.08 | −3.07 | −3.00 | −1.72 |
| Diluted shares (millions) | 10 | 17 | 20 | 23 | 24 | 24 | 26 | 28 | 30 |
| Cash flow | |||||||||
| Cash from operations | −32 | −34 | −30 | −12 | −28 | −52 | −88 | −58 | −51 |
| Capital expenditure | 1 | 2 | 6 | 2 | 2 | 3 | 8 | 6 | 6 |
| Free cash flow | −33 | −36 | −36 | −15 | −30 | −55 | −96 | −65 | −57 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 7 | 6 | 6 | 10 | 13 | 14 | 14 | 11 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 11 | 53 | 38 | 84 | 53 | 66 | 40 | 90 | 76 |
| Debt incl. finance leases | — | — | — | — | — | 176 | 189 | 0 | 248 |
| Total assets | 57 | 117 | 116 | 156 | 140 | 211 | 269 | 347 | 357 |
| Total liabilities | 62 | 47 | 77 | 81 | 89 | 219 | 250 | 294 | 334 |
| Shareholders' equity | −5 | 70 | 40 | 75 | 51 | −8 | 18 | 53 | 24 |
| Margins and ratios | |||||||||
| Gross margin | 51.0% | 59.0% | 61.2% | 62.0% | 67.4% | 65.9% | 64.8% | 66.0% | 69.3% |
| Operating margin | −57.6% | −39.0% | −34.5% | −33.0% | −19.8% | −24.5% | −39.4% | −30.1% | −18.5% |
| Net margin | −100.6% | −34.5% | −42.6% | −45.0% | −32.5% | −46.5% | −47.5% | −51.0% | −24.2% |
| Free cash flow margin | −94.8% | −58.2% | −40.5% | −17.3% | −23.6% | −34.0% | −58.4% | −38.9% | −27.0% |
| Rule of 40 (growth + FCF margin) | — | 18.3% | 5.8% | −22.7% | 26.0% | −6.4% | −56.2% | −38.4% | 0.2% |
| Return on capital | — | — | — | — | — | — | −38.3% | −60.8% | −39.0% |
| Return on equity | — | −65.5% | −69.9% | −66.5% | −65.5% | −353.5% | — | −236.7% | −133.2% |
| Return on assets | — | −24.3% | −32.7% | −27.9% | −27.8% | −42.9% | −32.7% | −27.5% | −14.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |